Title: Development and validation of a nomogram for predicting early recurrence in patients
undergoing different courses of postoperative adjuvant transarterial chemoembolisation
Version: 1 Date: 10 Mar 2025
Reviewer's report:
This study included 285 hepatocellular carcinoma (HCC) patients who underwent postoperative
adjuvant transarterial chemoembolization (PA-TACE) and developed a predictive model for
early recurrence based on different PA-TACE courses. Currently, there is no consensus
regarding the efficacy of postoperative adjuvant TACE, making this study highly relevant. The
research methodology is appropriate. The following are some suggestions:
1. What criteria were used to classify different PA-TACE courses? How do the characteristics
of patients differ across different PA-TACE treatment courses?
2. Are there high-risk HCC patients who did not receive PA-TACE? What is the postoperative
recurrence status of these patients?
3. What are the advantages of this predictive model compared to the conventional AJCC TNM
staging system?
4. In the patient inclusion criteria, the purpose of maximum tumor load (maximum diameter of
a single tumor lesion) to be confirmed before performing surgery is to identify high-risk HCC
patients for postoperative recurrence?. If so, why not use postoperative tumor size instead?
Title: Development and validation of a nomogram for predicting early recurrence in patients
undergoing different courses of postoperative adjuvant transarterial chemoembolisation
Version: 1 Date: 10 Mar 2025
Reviewer's report:
This study included 285 hepatocellular carcinoma (HCC) patients who underwent postoperative
adjuvant transarterial chemoembolization (PA-TACE) and developed a predictive model for
early recurrence based on different PA-TACE courses. Currently, there is no consensus
regarding the efficacy of postoperative adjuvant TACE, making this study highly relevant. The
research methodology is appropriate. The following are some suggestions:
1. What criteria were used to classify different PA-TACE courses? How do the characteristics
of patients differ across different PA-TACE treatment courses?
2. Are there high-risk HCC patients who did not receive PA-TACE? What is the postoperative
recurrence status of these patients?
3. What are the advantages of this predictive model compared to the conventional AJCC TNM
staging system?
4. In the patient inclusion criteria, the purpose of maximum tumor load (maximum diameter of
a single tumor lesion) to be confirmed before performing surgery is to identify high-risk HCC
patients for postoperative recurrence?. If so, why not use postoperative tumor size instead?
Please review this paper.
user
Title: Development and validation of a nomogram for predicting early recurrence in patients
undergoing different courses of postoperative adjuvant transarterial chemoembolisation
Version: 1 Date: 10 Mar 2025
Reviewer's report:
This study included 285 hepatocellular carcinoma (HCC) patients who underwent postoperative
adjuvant transarterial chemoembolization (PA-TACE) and developed a predictive model for
early recurrence based on different PA-TACE courses. Currently, there is no consensus
regarding the efficacy of postoperative adjuvant TACE, making this study highly relevant. The
research methodology is appropriate. The following are some suggestions:
1. What criteria were used to classify different PA-TACE courses? How do the characteristics
of patients differ across different PA-TACE treatment courses?
2. Are there high-risk HCC patients who did not receive PA-TACE? What is the postoperative
recurrence status of these patients?
3. What are the advantages of this predictive model compared to the conventional AJCC TNM
staging system?
4. In the patient inclusion criteria, the purpose of maximum tumor load (maximum diameter of
a single tumor lesion) to be confirmed before performing surgery is to identify high-risk HCC
patients for postoperative recurrence?. If so, why not use postoperative tumor size instead?
assistant